PT Data Sinergitama Jaya Tbk (IDX:ELIT)

Ligand Pharmaceuticals Income Statement

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	506,671	478,317	319,583	178,623	90,692	46,720
Revenue Growth (YoY)	28.25%	49.67%	78.92%	96.96%	94.12%	11.80%
Cost of Revenue	385,399	362,863	246,223	131,644	61,973	21,840
Gross Profit	121,272	115,454	73,360	46,979	28,719	24,880
Selling, General & Admin	75,506	53,222	39,772	24,096	14,005	15,394
Other Operating Expenses	-1,321	6,784	11,700	9,682	2,368	2,641
Operating Expenses	85,939	82,267	63,710	38,364	20,808	18,035
Operating Income	35,333	33,187	9,650	8,616	7,911	6,845
Interest Expense	-2,398	-1,768	-2,191	-805.37	-1,094	-2,063
Interest & Investment Income	-	-	122.2	32.29	26.84	34.87
Currency Exchange Gain (Loss)	-56.33	-1,235	-1,121	-	-1.45	2.84
Other Non Operating Income (Expenses)	6,260	4,775	15,735	4,601	460.01	32.23
EBT Excluding Unusual Items	39,139	34,960	22,195	12,444	7,302	4,852
Gain (Loss) on Sale of Assets	-124.6	-124.6	-	-	-	-
Pretax Income	39,014	34,835	22,195	12,444	7,302	4,852
Income Tax Expense	9,967	8,969	5,099	2,804	2,410	1,732
Earnings From Continuing Operations	29,047	25,866	17,096	9,640	4,892	3,120
Minority Interest in Earnings	-7.72	11.21	-52.02	72.59	-	-
Net Income	29,040	25,878	17,044	9,712	4,892	3,120
Net Income to Common	29,040	25,878	17,044	9,712	4,892	3,120
Net Income Growth	18.92%	51.83%	75.49%	98.54%	56.78%	-21.53%
Shares Outstanding (Basic)	2,032	2,024	2,031	688	520	520
Shares Outstanding (Diluted)	2,032	2,024	2,031	688	520	520
Shares Change (YoY)	-	-0.37%	195.31%	32.29%	-	-
EPS (Basic)	14.29	12.79	8.39	14.12	9.41	6.00
EPS (Diluted)	14.29	12.79	8.39	14.12	9.41	6.00
EPS Growth	18.92%	52.39%	-40.58%	50.08%	56.78%	-21.53%
Free Cash Flow	-14,644	33,560	-11,451	7,297	28,721	9,054
Free Cash Flow Per Share	-7.21	16.58	-5.64	10.61	55.23	17.41
Dividend Per Share	5.000	5.000	-	-	25.000	-
Gross Margin	23.94%	24.14%	22.96%	26.30%	31.67%	53.25%
Operating Margin	6.97%	6.94%	3.02%	4.82%	8.72%	14.65%
Profit Margin	5.73%	5.41%	5.33%	5.44%	5.39%	6.68%
Free Cash Flow Margin	-2.89%	7.02%	-3.58%	4.08%	31.67%	19.38%
EBITDA	56,983	45,427	19,300	11,472	10,891	8,992
EBITDA Margin	11.25%	9.50%	6.04%	6.42%	12.01%	19.25%
D&A For EBITDA	21,650	12,239	9,651	2,857	2,981	2,148
EBIT	35,333	33,187	9,650	8,616	7,911	6,845
EBIT Margin	6.97%	6.94%	3.02%	4.82%	8.72%	14.65%
Effective Tax Rate	25.55%	25.75%	22.97%	22.53%	33.01%	35.69%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.